MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality

Eur J Pharmacol. 2015 Oct 5:764:173-188. doi: 10.1016/j.ejphar.2015.07.007. Epub 2015 Jul 2.

Abstract

AT1 antagonists effectively prevent atherosclerosis since AT1 upregulation and angiotensin II-induced proinflammatory actions are critical to atherogenesis. Despite the classic mechanisms underlying the vasoprotective and atheroprotective actions of AT1 antagonists, the cross-talk between angiotensin-converting enzyme-angiotensin II-AT1 and angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axes suggests other mechanisms beyond AT1 blockage in such effects. For instance, angiotensin-converting enzyme 2 activity is inhibited by reactive oxygen species derived from AT1-mediated proinflammatory signaling. Since angiotensin-(1-7) promotes antiatherogenic effects, we hypothesized that the vasoprotective and atheroprotective effects of AT1 antagonists could result from their inhibitory effects on the AT1-mediated negative modulation of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. Interestingly, our results showed that early atherosclerosis triggered in thoracic aorta from high cholesterol fed-Apolipoprotein E-deficient mice impairs angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality by a proinflammatory-redox AT1-mediated pathway. In such mechanism, AT1 activation leads to the aortic release of tumor necrosis factor-α, which stimulates NAD(P)H oxidase/Nox1-driven generation of superoxide and hydrogen peroxide. While hydrogen peroxide inhibits angiotensin-converting enzyme 2 activity, superoxide impairs MAS functionality. Candesartan treatment restored the functionality of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis by inhibiting the proinflammatory-redox AT1-mediated mechanism. Candesartan also promoted vasoprotective and atheroprotective effects that were mediated by MAS since A779 (MAS antagonist) co-treatment inhibited them. The role of MAS receptors as the final mediators of the vasoprotective and atheroprotective effects of candesartan was supported by the vascular actions of angiotensin-(1-7) upon the recovery of the functionality of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis.

Keywords: AT(1) receptors; Angiotensin-(1-7); Angiotensin-converting-enzyme 2; Candesartan; Early atherosclerosis; MAS receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin I / metabolism*
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Angiotensin-Converting Enzyme 2
  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism
  • Aorta, Thoracic / pathology
  • Apolipoproteins E / genetics
  • Atherosclerosis / blood
  • Atherosclerosis / pathology
  • Benzimidazoles / pharmacology*
  • Biphenyl Compounds
  • Cardiotonic Agents / pharmacology*
  • Cholesterol / blood
  • Cytokines / genetics
  • Cytokines / metabolism
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NADH, NADPH Oxidoreductases / metabolism
  • NADPH Oxidase 1
  • Peptide Fragments / metabolism*
  • Peptidyl-Dipeptidase A / metabolism*
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / metabolism*
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptors, G-Protein-Coupled / metabolism*
  • Tetrazoles / pharmacology*
  • Triglycerides / blood
  • Vascular Cell Adhesion Molecule-1 / genetics

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Apolipoproteins E
  • Benzimidazoles
  • Biphenyl Compounds
  • Cardiotonic Agents
  • Cytokines
  • Peptide Fragments
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Receptor, Angiotensin, Type 1
  • Receptors, G-Protein-Coupled
  • Tetrazoles
  • Triglycerides
  • Vascular Cell Adhesion Molecule-1
  • Angiotensin I
  • Cholesterol
  • NADH, NADPH Oxidoreductases
  • NADPH Oxidase 1
  • NOX1 protein, mouse
  • Peptidyl-Dipeptidase A
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2
  • angiotensin I (1-7)
  • candesartan